| |
The press had reports on January 14, 2003 that Wockhardt Limited and Japanese company Eisai are in talks to broaden their alliance to include exports from India to Japan, and a possible collaboration on research and development (R&D).
The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.
Wockhardt Limited has vide its letter inter-alia stated, "You may please note that the company is expanding its activities in the domestic and international market by entering into marketing arrangements for various products manufactured by other companies to be marketed in India by Wockhardt or Wockhardt's products to be marketed by other companies in India or abroad. As a major step towards this objective the Company had entered into a marketing arrangement with Esai Japan for marketing of its' nerve disorder product, Methycobal.
In view of the success received by the Company in marketing this product, it is considering to expand the portfolio. Wockhardt has been in the forefront of Research and development activities in the pharmaceutical industry in India and has a comprehensive multi-faceted R&D programme. Wockhardt has spent over Rs. 200 crores on R&D over last five years alone and spends over 7% of sales on R&D on ongoing basis. As a result of the Company's spend on R&D, it has developed and marketed Hepatitis-B vaccine and is now in the process of obtaining approval for Combination vaccine. The Company also considers that an alliance in the field of R&D can lead to substantial achievements."
Top
The press had reports on January 14, 2003 that Lupin Limited is gearing up to foray into over-the-counter (OTC) drugs segment and has decided to unveil a separate division for it in the next fiscal.
The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.
Lupin Limited has vide its letter inter-alia stated, "In this regard, we wish to state that the Company continuously explores various opportunities to expand the business horizon and enhance the depth of the market reach of its products. One of the means of achieving this objective is by setting-up an Over-the-Counter (OTC) division. What has been quoted in the said article is of a general nature and is basically indicative of the broad direction in which the Company plans to move. While the Company may consider this option, we wish to assure you that concrete steps have not been taken in this direction. We hereby assure you that once a firm plan is approved by the Company, we shall promptly keep you informed on priority basis."
Top
The press had reports on January 14, 2003 that Geometric Software Solutions Limited has formed a global alliance with EDS. The alliance will enable the company to bid for all CAD/CAM related projects that EDS undertakes and bring them offshore to its Indian development centre.
The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.
Geometric Software Solutions Limited has vide its letter inter-alia stated, "A significant development this quarter includes signing of a Professional Services Agreement with EDS."
Top
The press had reports that the Britain's National Health Service (NHS) may take civil action against producers of penicillin-based antibiotics such as Ranbaxy for overpricing.
The Exchange in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded had written to the officials of the company.
Ranbaxy Laboratories Limited has vide its letter inter-alia stated, "In this regard, we wish to inform you that neither the Company nor its UK based subsidiary has received any notice for any civil action in regard to pricing of Penicillin based drugs in UK."
Top
The Exchange has successfully completed its 723rd Normal Settlement (Rolling T+3 following SEBI directive) since inception i.e., Settlement Number N - 2003008 on January 15, 2003. The settlement statistics are as follows:
| Particulars |
Values |
| |
N - 2003008 |
| Total traded quantity (lakhs) |
1708.56 |
| Total traded value (Rs. In Crores) |
3630.60 |
| Total value of the settlement (Securities) (Rs. In Crores) |
558.83 |
| Total value of the settlement (Funds) (Rs. In Crores) |
206.47 |
| Shortages for the settlement |
0.37% |
| % of Delivery ( No. of shares delivered / No. of shares traded ) |
22.92% |
Top
|
|